CIM
ALNY icon

Cambria Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cambria Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Buy
1,059
+40
+4% +$12.1K 0.02% 580
2026
Q1 		$337K Buy
+1,019
New +$347K 0.02% 486
2015
Q4 		– Sell
-101
Closed -$8K – 160
2015
Q3 		$8K Hold
101
– – ﹤0.01% 295
2015
Q2 		$12K Buy
101
+83
+461% +$9.92K ﹤0.01% 229
2015
Q1 		$2 Buy
+18
New +$1.82K ﹤0.01% 228

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambria Investment Management's ALNY Position: Q2 2026 in Review

Cambria Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 3.9% in Q2 2026, buying an estimated $12.1K and bringing the position to 1,059 shares worth $319K. The position accounts for 0.02% of the portfolio, ranked #580.

Cambria Investment Management first reported a position in ALNY in Q1 2015 and has held it in 5 quarters since. The position peaked at $337K in Q1 2026. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cambria Investment Management held 1,059 shares of Alnylam Pharmaceuticals worth $319K as of Q2 2026.
  • Cambria Investment Management bought 40 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Alnylam Pharmaceuticals made up 0.02% of Cambria Investment Management's portfolio in Q2 2026, its #580 holding.
  • Cambria Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
  • Cambria Investment Management's Alnylam Pharmaceuticals position peaked at $337K in Q1 2026.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.